- Home
- PTGX vs IMCR Comparison
PTGX vs IMCR Comparison
Compare PTGX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- IMCR
- Stock Information
- Founded
- PTGX 2006
- IMCR 2008
- Country
- PTGX United States
- IMCR United Kingdom
- Employees
- PTGX N/A
- IMCR N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTGX Health Care
- IMCR Health Care
- Exchange
- PTGX Nasdaq
- IMCR Nasdaq
- Market Cap
- PTGX 2.9B
- IMCR 1.5B
- IPO Year
- PTGX 2016
- IMCR 2021
- Fundamental
- Price
- PTGX $50.17
- IMCR $32.77
- Analyst Decision
- PTGX Strong Buy
- IMCR Buy
- Analyst Count
- PTGX 9
- IMCR 10
- Target Price
- PTGX $67.11
- IMCR $58.13
- AVG Volume (30 Days)
- PTGX 1.0M
- IMCR 445.1K
- Earning Date
- PTGX 08-05-2025
- IMCR 08-07-2025
- Dividend Yield
- PTGX N/A
- IMCR N/A
- EPS Growth
- PTGX N/A
- IMCR N/A
- EPS
- PTGX 0.86
- IMCR N/A
- Revenue
- PTGX $207,801,000.00
- IMCR $333,581,000.00
- Revenue This Year
- PTGX N/A
- IMCR $26.82
- Revenue Next Year
- PTGX $47.15
- IMCR $8.15
- P/E Ratio
- PTGX $58.21
- IMCR N/A
- Revenue Growth
- PTGX N/A
- IMCR 25.75
- 52 Week Low
- PTGX $32.50
- IMCR $23.15
- 52 Week High
- PTGX $60.60
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- PTGX 61.93
- IMCR 45.73
- Support Level
- PTGX $52.16
- IMCR $30.76
- Resistance Level
- PTGX $57.24
- IMCR $32.55
- Average True Range (ATR)
- PTGX 1.71
- IMCR 1.39
- MACD
- PTGX -0.25
- IMCR -0.41
- Stochastic Oscillator
- PTGX 55.96
- IMCR 19.09
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.